Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker

FHS
June 12, 2024
10:52 am

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis1.

What STAT readers think about premed requirements, too much health care, harm reduction, and more

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a

November 18, 2023

Severe COVID in Kids

It’s easy to think the COVID-19 pandemic is in the rearview mirror, especially for children who are often considered at low risk for severe disease.

October 5, 2024

Pulled Myeloma Drug May Have a Role in Treating the Disease After All

A little more than a year after belantamab mafodotin (Blenrep), an anti-B-cell maturation antigen (BCMA) monoclonal antibody, was withdrawn from the market for patients with

February 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.